Eikonoklastes completes a license to add novel gene therapy for treating neurodegenerative diseases

By | January 20, 2022
Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company, today announced it has completed a license with the University of California San Diego to add a novel gene therapy for the treatment of neurodegenerative diseases.